tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Buy Rating Maintained for Iterum Therapeutics Despite Initial Challenges, Driven by Unique Market Position of ORLYNVAH
PremiumRatingsBuy Rating Maintained for Iterum Therapeutics Despite Initial Challenges, Driven by Unique Market Position of ORLYNVAH
30d ago
Iterum Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Iterum Therapeutics Reports Q3 2025 Financial Results
1M ago
Iterum Therapeutics’ Earnings Call: Optimism Amid Challenges
Premium
Company Announcements
Iterum Therapeutics’ Earnings Call: Optimism Amid Challenges
1M ago
Iterum Therapeutics Advances Adolescent Antibiotic Trial: Key Insights for Investors
PremiumCompany AnnouncementsIterum Therapeutics Advances Adolescent Antibiotic Trial: Key Insights for Investors
2M ago
Iterum Therapeutics Announces $20M Share Offering
Premium
Company Announcements
Iterum Therapeutics Announces $20M Share Offering
2M ago
Iterum Therapeutics sees cash runway into 2026
Premium
The Fly
Iterum Therapeutics sees cash runway into 2026
3M ago
Iterum Therapeutics’ Earnings Call: Optimism Amid Challenges
PremiumCompany AnnouncementsIterum Therapeutics’ Earnings Call: Optimism Amid Challenges
4M ago
Buy Rating for Iterum Therapeutics: Strategic Positioning and Growth Potential with ORLYNVAH Launch
Premium
Ratings
Buy Rating for Iterum Therapeutics: Strategic Positioning and Growth Potential with ORLYNVAH Launch
4M ago
Iterum Therapeutics Prepares for ORLYNVAH™ Launch
Premium
Company Announcements
Iterum Therapeutics Prepares for ORLYNVAH™ Launch
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100